Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Phathom Pharmaceuticals (PHAT) FCF Margin (2022 - 2025)

Phathom Pharmaceuticals (PHAT) has disclosed FCF Margin for 4 consecutive years, with 8.99% as the latest value for Q4 2025.

  • Quarterly FCF Margin rose 20451.0% to 8.99% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 95.37% through Dec 2025, up 38747.0% year-over-year, with the annual reading at 95.37% for FY2025, 38747.0% up from the prior year.
  • FCF Margin for Q4 2025 was 8.99% at Phathom Pharmaceuticals, up from 28.38% in the prior quarter.
  • The five-year high for FCF Margin was 1626.57% in Q1 2022, with the low at 6254.55% in Q4 2023.
  • Average FCF Margin over 4 years is 695.45%, with a median of 159.04% recorded in 2025.
  • The sharpest move saw FCF Margin tumbled -667685bps in 2023, then surged 604104bps in 2024.
  • Over 4 years, FCF Margin stood at 422.31% in 2022, then crashed by -1581bps to 6254.55% in 2023, then surged by 97bps to 213.5% in 2024, then skyrocketed by 96bps to 8.99% in 2025.
  • According to Business Quant data, FCF Margin over the past three periods came in at 8.99%, 28.38%, and 159.04% for Q4 2025, Q3 2025, and Q2 2025 respectively.